<DOC>
	<DOCNO>NCT00457808</DOCNO>
	<brief_summary>The purpose study determine rapamycin reduce angiomyolipomata volume patient tuberous sclerosis complex lam .</brief_summary>
	<brief_title>Rapamycin Therapy Patients With Tuberous Sclerosis Complex Sporadic LAM</brief_title>
	<detailed_description>The study design open label , phase I/II trial sirolimus one year follow one year therapy.Patients see baseline , two week four week , 2,4,6,9,12,18 24 month . Angiomyolipomata image perform two four week visit . Complete pulmonary function test six-minute walk obtain baseline,6 9 month , 12 24 month visit , simple spirometry perform visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Diagnosed angiomyolipomas either Tuberous Sclerosis complex Lymphangioleiomyomatosis Between gaes 18 65 year Competency voluntarily consent Clinically definite diagnosis tuberous sclerosis SLAM Adequate contraception At least one angiomyolipoma 1 cm great large diameter Use continuous supplemental oxygen Concurrent infection Recent surgery Ongoing plan pregnancy Lactation Use investigational drug within last 30 day study entrance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>TSC LAM</keyword>
	<keyword>Tuberous Sclerosis Complex sporadic LAM</keyword>
</DOC>